Press Releases

Financial Information

bioMérieux – 2024 Financial Results

Consolidated sales amounted to €3,980 million in 2024, up 10.3% like-for-like from €3,675 million in the prior year period. Reported growth stood at +8.3% for the period.

Press Release

bioMérieux launches GENE-UP® TYPER, an innovative diagnostic solution for food industries to rapidly analyze the root cause of contamination of Listeria monocytogenes

bioMérieux, a world leader in the field of in vitro diagnostics, today announces the launch of GENE-UP® TYPER, a real-time PCR solution for rapid root cause analysis in the food industry.

Press Release

bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid

bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid has obtained clearance from the U.S. Food and Drug Administration (FDA). This midplex molecular panel tests for 11 of the most common bacteria, viruses, and parasites associated with gastroenteritis — all from one sample, with results available in approximately one hour.

Press Release

bioMérieux strengthens its point of care presence with the acquisition of the immunoassay start-up SpinChip

bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has entered into an agreement to acquire SpinChip Diagnostics ASA (“SpinChip”), a privately held Norwegian diagnostics company that has developed a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted to near patient testing as it can deliver a result from a whole blood sample within 10 minutes with the same high-sensitivity performance as the laboratory instruments.

Press Release

bioMérieux to present at the 43rd Annual J.P. Morgan HealthCare Conference

Marcy l’Étoile, France, January 13, 2025 – bioMérieux, a world leader in the field in vitro diagnostics, today announces its participation in the 43rd Annual J.P. Morgan Healthcare Conference, to be held in San Francisco, USA, from January 13 to 16, 2025.

BIOFIRE® FILMARRAY® Tropical Fever Panel, a syndromic PCR test targeting causes of tropical fever infections, receives U.S. FDA Special 510(k) clearance

bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® FILMARRAY® Tropical Fever (TF) Panel has received U.S. Food and Drug Administration (FDA) Special 510(k) clearance. This innovative polymerase-chain reaction (PCR) testing solution offers fast and accurate pathogen identification in patients with unexplained fever, helping to optimize treatment overall.